Source study unconfirmed
Story checked
New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026 (opens in a new tab)
news-medical.net · 2026-11-06
Short answer
Source study unconfirmedStudy not confirmed.
The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
Help improve NewsLink
Tell us what worked or what needs attention in this check.
The story
New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
news-medical.net · 2026-11-06
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No single source study could be confirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
View article claimsSearch result
Source study unconfirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Also referencedpresented as the new finding
New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
- Also referencedpresented as the new finding
https://onlineprogram.hematology.org/?_gl=1*1ncsvd5*_gcl_au*MjA5MDI5MjI5LjE3OTMxOTY3NzA.*_ga*MjA3OTI1NzU4MS4xNzkzMTk2Nzcw*_ga_8L7E6EDKVZ*czE3OTM4MDEzNDgkbzQkZzEkdDE3OTM4MDE0NzMkajE3JGwwJGgw
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedOncopeptides says two abstracts on real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma have been accepted for presentation at the 68th ASH Annual Meeting in 2026.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 7Not checkedThe two independent multicenter retrospective studies from Spain and Italy included a total of 82 heavily pretreated RRMM patients and are presented as real-world evidence supporting Pepaxti plus dexamethasone in European clinical practice.View evidenceHide evidence
As stated82 patients
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 7Not checkedThe company says the data reinforce Pepaxti's clinical utility and manageable safety profile, including in the setting after T-cell-redirecting immunotherapies such as anti-BCMA and anti-GPRC5D agents and between immunotherapies.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 7Not checkedIn the Spanish registry analysis, 40 patients with complete follow-up data treated between 2023 and 2026 had an overall response rate of 32.5%, median duration of response of 8.3 months, median progression-free survival of 3.2 months, and median overall survival of 15.7 months.View evidenceHide evidence
As statedORR 32.5%; mDoR 8.3 months; mPFS 3.2 months; mOS 15.7 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 7Not checkedAmong evaluable Spanish patients previously exposed to anti-BCMA and/or anti-GPRC5D therapies, the reported overall response rate was 26%, with median duration of response of 5.8 months, median progression-free survival of 3.0 months, and median overall survival of 23.2 months.View evidenceHide evidence
As statedORR 26%; mDoR 5.8 months; mPFS 3.0 months; mOS 23.2 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 7Not checkedIn the Italian multicenter early access study, 42 RRMM patients had an overall response rate of 48%, including deep hematologic responses and stable disease, with median progression-free survival of 5.02 months and median overall survival of 13.51 months.View evidenceHide evidence
As statedORR 48%; mPFS 5.02 months; mOS 13.51 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 7 of 7Not checkedThe Italian study reports that 67% of patients proceeded to subsequent therapy, including anti-BCMA bispecific antibodies, anti-GPRC5D bispecific antibodies, and CAR-T cell therapy after melflufen-dexamethasone bridging, and that tolerability was generally predictable and manageable.View evidenceHide evidence
As stated67% proceeded to subsequent therapy
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies.
Clinical Lymphoma, Myeloma & Leukemia · 2026 · PubMed, Europe PMC, Crossref
Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.
Journal of Clinical Oncology · 2026 · Crossref
Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.
European Journal of Haematology · 2026 · PubMed, Europe PMC
P-036 BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy
Clinical Lymphoma Myeloma and Leukemia · 2024 · Crossref
Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
European Journal of Haematology · 2025 · PubMed